Mostrar el registro sencillo del ítem

dc.contributor.authorMarrero, Ana Dácil
dc.contributor.authorCastilla, Laura
dc.contributor.authorEspartero, José L.
dc.contributor.authorMadrona, Andrés
dc.contributor.authorQuesada, Ana R.
dc.contributor.authorMedina, Miguel Ángel 
dc.contributor.authorMartínez-Poveda, Beatriz
dc.date.accessioned2020-09-22T10:10:29Z
dc.date.available2020-09-22T10:10:29Z
dc.date.created2020-09
dc.date.issued2020-09-22
dc.identifier.urihttps://hdl.handle.net/10630/19821
dc.descriptionVersión preprint del manuscrito de los autores, publicado finalmente en: Food Chemistry 333 (2020) 127476 con DOI: 10.1016/j.foodchem.2020.127476en_US
dc.description.abstractThe phenolic compound hydroxytyrosol and its derivatives are responsible for some of the health benefits of the intake of virgin olive oil, having shown antiangiogenic properties. In this study, we explored the antiangiogenic potential of six synthetic hydroxytyrosyl alkyl ethers (HT C1, C2, C4, C6, C8 and C12). Our results showed that all compounds affected endothelial cell viability in vitro at low micromolar doses. In addition, compounds HT C1, C2, C4 and C6 inhibited endothelial cell migration and formation of tubular-like structures. In these assays, hydroxytyrosyl hexyl ether (HT C6) exhibited the most potent inhibitory activity in vitro, activating as well apoptosis in endothelial cells. Furthermore, the antiangiogenic activity of HT C6 was confirmed in vivo in the chick chorioallantoic membrane assay. Hence, we present hydroxytyrosol synthetic derivative HT C6 as a new antiangiogenic compound and as a good candidate for an antiangiogenic drug in the treatment of angiogenesisdependent diseases.en_US
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Science, Innovation and Universities (grants AGL2007-66373 and PID2019- 105010RB-I00), Andalusian Government and FEDER (P12-CTS-1507, UMA18-FEDERJA-220 and funds from group BIO 267), as well as funds from the University of Málaga (“Plan Propio de Investigación y Transferencia”). The “CIBER de Enfermedades Raras” and “CIBER de Enfermedades Cardiovasculares” are initiatives from the ISCIII (Spain). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectNeovascularizaciónen_US
dc.subjectAceite de olivaen_US
dc.subject.otherAngiogenesisen_US
dc.subject.otherHydroxytyrosyl alkyl ethersen_US
dc.subject.otherExtra virgin olive oilen_US
dc.titleA comparative study of the antiangiogenic activity of hydroxytyrosyl alkyl ethersen_US
dc.typeinfo:eu-repo/semantics/preprinten_US
dc.centroFacultad de Cienciasen_US
dc.identifier.doi10.1016/j.foodchem.2020.127476
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional